Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms the legality and compliance of Hefei Xueqi Electric Co., Ltd.'s plan to repurchase and cancel part of the restricted stocks under the 2025 incentive plan, as well as the adjustment of the repurchase price [1][5][8] Summary by Relevant Sections Approval and Authorization of Repurchase and Adjustment - The 2025 incentive plan has undergone necessary procedures and was approved by the company's board of directors [3][4] - The board has authorized the repurchase of 8,000 shares of restricted stock from a departing incentive object and adjusted the repurchase price to 7.17 yuan per share [4][5] Specifics of the Repurchase and Adjustment - The repurchase is due to one incentive object leaving the company, which triggers the cancellation of their unvested restricted stocks [6][8] - The adjustment of the repurchase price is based on the company's profit distribution plan, which included a cash dividend of 1.2 yuan per 10 shares [6][7] Conclusion - The necessary approvals and authorizations for the repurchase and adjustment have been obtained, and the actions comply with relevant regulations [5][8] - The company must still obtain shareholder approval and fulfill disclosure obligations regarding the repurchase [8]

证券代码：301123 证券简称：奕东电子 公告编码：2025-050 奕东电子科技股份有限公司 关于向公司2025年限制性股票激励计划激励对象 授予限制性股票的公告 特别提示: 票 22.50 万股 均为 13.55 元/股 奕东电子科技股份有限公司（以下简称"公司"）2025年限制性股票激励计划 （以下简称"本激励计划"、"本次激励计划"或"《激励计划》"）规定的限制 性股票授予条件已经成就，根据公司2025年第一次临时股东会的授权，公司于 会议，审议通过了《关于向激励对象授予限制性股票的议案》，确认同意以2025 年8月27日为授予日，向5名激励对象授予104.00万股第一类限制性股票，授予价 格为13.55元/股；向10名激励对象授予22.50万股第二类限制性股票，授予价格为 一、本次激励计划简述 公司于 2025 年 8 月 19 日召开了 2025 年第一次临时股东会，会议审议通过 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 了《关于 <奕东电子科技股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草 案=" ...

Core Viewpoint - The company plans to repurchase and cancel a total of 481,978 restricted stocks from its 2024 incentive plan due to the disqualification of seven incentive targets who have left or retired from the company [1][2][10]. Summary by Sections Reasons for Repurchase - The repurchase is due to seven individuals no longer meeting the criteria for incentive targets, with two leaving voluntarily, two having their contracts terminated by mutual agreement, and three retiring [2][7][10]. Quantity and Nature of Stocks - The total number of restricted stocks to be repurchased is 481,978 shares, which will reduce the company's total share capital from 778,991,206 shares to 778,509,228 shares [1][10]. Impact on Company - After the completion of the repurchase, the structure of the company's shares will change, with limited shares decreasing from 8,003,256 to 7,521,278, while unlimited shares remain unchanged at 770,987,950 [10]. Approval Process - The repurchase proposal was approved by the Compensation and Assessment Committee and the Board of Directors, with unanimous votes in favor during meetings held on August 27, 2025 [11].

Core Insights - Fortior (01304) reported a mid-year performance for 2025, with revenue approximately 375 million, representing a year-on-year increase of 32.8% [1] - Gross profit was around 195 million, showing a year-on-year growth of 31.1% [1] - Net profit stood at 116.5 million, reflecting a year-on-year decline of 4.5%, with basic earnings per share at 1.26 [1] - The decrease in net profit was primarily due to the implementation of a restricted stock incentive plan in November 2024, which led to an increase in share-based payment expenses by approximately 32 million year-on-year; excluding this factor, the group's profit would have increased by 18.7% year-on-year [1] Financial Performance - Revenue: Approximately 375 million, up 32.8% year-on-year [1] - Gross Profit: Approximately 195 million, up 31.1% year-on-year [1] - Net Profit: 116.5 million, down 4.5% year-on-year [1] - Basic Earnings Per Share: 1.26 [1] Incentive Plan Impact - The restricted stock incentive plan implemented in November 2024 resulted in an increase of share-based payment expenses by approximately 32 million year-on-year [1] - Adjusted for this expense, the group's profit would have shown an increase of 18.7% year-on-year [1]

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Core Viewpoint - The Shenzhen BGI Genomics Co., Ltd. is holding its third extraordinary general meeting of shareholders in 2025 to discuss and vote on several key proposals, including amendments to the 2024 restricted stock incentive plan and the employee stock ownership plan, aimed at enhancing employee motivation and aligning interests with shareholders [5][22]. Group 1: Meeting Procedures - The meeting will ensure the legal rights of all shareholders and maintain order and efficiency, following relevant laws and regulations [1][2]. - Attendees must register and confirm their participation before the meeting starts, as latecomers will not be allowed to vote [2][3]. - The meeting will follow a predetermined agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][4]. Group 2: Proposals and Amendments - Proposal One involves the revision of the 2024 restricted stock incentive plan, which aims to enhance performance assessment indicators at the company level [7][9]. - The revision is driven by the need to adapt to external market changes and to focus on increasing market share in the gene sequencing equipment sector, which is crucial for future revenue growth [9][10]. - Proposal Two addresses the amendments to the 2024 employee stock ownership plan, which also includes new performance assessment indicators to improve governance and employee engagement [16][17]. Group 3: Performance Assessment Criteria - The performance assessment for the incentive plans will be based on revenue growth rates, excluding impacts from public health events, with specific targets set for 2024 and 2025 [9][19]. - The revised criteria will include metrics related to gene sequencing equipment sales, emphasizing the importance of capturing market share to secure long-term customer value [10][18]. - The company aims to ensure that the revised performance targets remain challenging yet achievable, fostering a sustainable growth environment [20][21].

Core Viewpoint - The company is undertaking a repurchase and cancellation of a portion of its A-share restricted stock, along with an adjustment to the repurchase price, in accordance with relevant laws and regulations [2][19]. Group 1: Legal Framework and Procedures - The legal opinion is based on the Company Law, Securities Law, and the Management Measures for Equity Incentives issued by the China Securities Regulatory Commission [2][3]. - The company has followed necessary procedures for the repurchase and cancellation of restricted stock, including obtaining approvals from the board and independent directors [5][9]. Group 2: Repurchase Details - The total number of restricted stocks to be repurchased and canceled is 5,228,180 shares, which includes stocks from four individuals who have terminated their labor contracts and stocks from others due to unmet performance targets [9][12]. - The repurchase price for the first grant of restricted stocks is set at 3.43395 CNY per share, while the price for the reserved grant is 3.87395 CNY per share [13][16]. Group 3: Financial Implications - The total funds allocated for this repurchase amount to approximately 18,180,700.71 CNY, sourced from the company's own funds [16][18]. - Following the completion of the repurchase, the company's total share capital will decrease from 877,143,737 shares to 871,915,557 shares [17][18]. Group 4: Conclusion and Compliance - The company has met the necessary approvals and authorizations for the repurchase and cancellation of restricted stocks, ensuring compliance with relevant laws and internal regulations [19].

Core Viewpoint - The company plans to repurchase and cancel a total of 5,228,180 restricted shares from 279 incentive targets, which represents approximately 0.596% of the company's total share capital of 877,143,737 shares [1][9][14]. Summary by Sections Repurchase Details - The repurchase involves 5,228,180 restricted shares that have been granted but not yet released from restrictions, affecting 279 incentive targets [1][6]. - The repurchase price for the first grant of restricted shares is set at 3.43395 CNY per share, while the reserved grant price is 3.87395 CNY per share [1][12]. - The total funds allocated for this repurchase amount to approximately 18,180,700.71 CNY, sourced from the company's own funds [1][13]. Approval Process - The repurchase plan was approved by the company's board and the remuneration committee, following the authorization from the 2021 and 2022 shareholder meetings [2][4]. - Independent directors provided their opinions on the repurchase plan, affirming its compliance with relevant regulations [2][15]. Reasons for Repurchase - The repurchase is necessitated by the termination of labor contracts for some incentive targets and the failure to meet performance targets for the third release period [6][9]. - Specifically, four incentive targets will have their shares repurchased due to contract terminations, and the remaining shares are due to unmet performance criteria [7][9]. Impact on Share Capital - Following the completion of the repurchase, the company's total share capital will decrease from 877,143,737 shares to 871,915,557 shares [14][15]. - The repurchase will not alter the control of the company or its compliance with listing conditions [15]. Legal Compliance - The company has obtained necessary approvals and authorizations for the repurchase, ensuring compliance with the relevant management regulations and the incentive plan [16].

北京市建国门北大街 8 号华润大厦 20 层 邮编：100005 电话：(86-10) 8519-1300 传真：(86-10) 8519-1350 junhebj@junhe.com 北京市君合律师事务所 关于 北京致远互联软件股份有限公司 的 法律意见书 对于本所无法独立查验的事实，本所律师依赖政府有关部门、致远互联及其 他相关方出具的有关证明、说明文件。 在本法律意见书中，本所律师仅对本法律意见书出具之日以前已经发生或存 在的且与本次作废有关的重要法律问题发表法律意见，并不对其他问题以及会 计、审计、投资决策、业绩考核目标等专业事项发表意见。本法律意见书系以中 国法律为依据出具，且仅限于本法律意见书出具之前已公布且现行有效的中国法 律。本法律意见书不对境外法律或适用境外法律的事项发表意见。本所律师在本 法律意见书中对于有关会计、审计等专业文件（包括但不限于审计报告等）之内 容的引用，并不意味着本所律师对该等专业文件以及所引用内容的真实性、准确 性做出任何明示或默示的保证，本所律师亦不具备对该等专业文件以及所引用内 容进行核查和判断的专业资格。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理 ...